Today's important announcements for Hong Kong stocks:
1) Performance Express
$MEITUAN-W (03690.HK)$ Q4 revenue was 88.487 billion yuan, up 20.1% year on year; adjusted net profit for Q4 was 9.849 billion yuan, up 125.1% year over year.
$MNSO (09896.HK)$: Revenue in 2024 was 16.994 billion yuan, up 22.8% year on year; net profit was 2.618 billion yuan, up 16.17% year on year, with a net opening of 1,219 new stores throughout the year.
$NIO-SW (09866.HK)$: Revenue in 2024 was 65.7316 billion yuan, up 18.2% year over year. Among them, automobile sales in the fourth quarter were 17.4756 billion, up 13.2% year on year and 4.7% month on month.
NIO's total revenue in Q4 2024 reached 19.703 billion yuan (2.699 billion US dollars), up 15.2% year on year; Q4 delivered a record high of 72,689 vehicles, up 45.2% year on year, with a net loss of 7.112 billion yuan, an increase of 32.5% year on year. Delivery guidelines for the first quarter of 2025 were 0.041 million vehicles to 0.043 million vehicles, an increase of about 36.4% to about 43.1% year over year.
$HORIZONROBOT-W (09660.HK)$: Revenue in 2024 was 2.384 billion yuan, up 53.6% year on year; gross profit was 1.841 billion yuan, up 68.3% year on year. In 2024, it obtained fixed points for more than 100 models, and the total number of fixed points for the cumulative number of models increased to more than 310 models.
$BLOKS (00325.HK)$: Revenue in 2024 was 2.241 billion yuan, up 155.6% year on year; adjusted annual profit was 0.585 billion yuan, up 702.1% year on year.
$COSCO SHIP PORT (01199.HK)$: Revenue in 2024 was 1.503 billion US dollars, up 3.3% year on year; net profit was 0.309 billion US dollars, down 4.8% year on year. Total throughput increased 6.1% year over year to 0.144 billion TEU during the period.
$BANKCOMM (03328.HK)$: Net operating income in 2024 was 260.269 billion yuan, up 0.87% year on year; net profit was 93.586 billion yuan, up 0.93% year on year.
$TCL ELECTRONICS (01070.HK)$: In 2024, revenue was HK$99.322 billion, up 25.7% year over year; net profit was HK$1.759 billion, up 136.6% year over year. Mainly due to the year-on-year increase in shipment volume, the product structure continued to improve.
$GREENTOWN SER (02869.HK)$: Revenue in 2024 was 17.893 billion yuan, up 6.43% year on year; net profit was 0.785 billion yuan, up 29.69% year on year.
$DINGDANG HEALTH (09886.HK)$: Revenue in 2024 was 4.669 billion yuan, a year-on-year decrease of 3.87%; loss was 0.376 billion yuan, an increase of 66.73% year-on-year.
$HANSOH PHARMA (03692.HK)$: Revenue in 2024 was 12.261 billion yuan, up 21.35% year on year; net profit was 4.372 billion yuan, up 33.39% year on year. This is mainly due to increased revenue from innovative drugs and cooperative products.
$C-MER MEDICAL (03309.HK)$: Revenue of HK$1.913 billion in 2024, a year-on-year decrease of 0.56%; net loss of HK$0.135 billion.
$WEIMOB INC (02013.HK)$: Revenue of about 1.339 billion yuan was achieved in 2024; adjusted net loss was about 0.533 billion yuan, a year-on-year decrease of 3%.
During the period, Weimeng WAI's monthly active customers increased by 74.0% month-on-month, the number of core function users increased by 248.0% year-on-year, and the adoption rate of AI-generated copy and images increased by 53.4% and 13.4%, respectively.
$SCHOLAR EDU (01769.HK)$: Revenue in 2024 was 0.852 billion yuan, up 49.37% year on year; net profit was 0.146 billion yuan, up 69.38% year on year. This is mainly due to the increase in total tutoring hours, which has led to an increase in revenue and the Group's continuous efforts to improve operational efficiency.
$ANTENGENE-B (06996.HK)$: Revenue in 2024 was 91.95 million yuan, up 36.62% year on year; loss was 0.319 billion yuan, down 45.07% year on year.
$SCIENTECH (02291.HK)$: Expected net profit in 2024 is 0.23-0.26 billion yuan.
$MIDEA REAL EST (03990.HK)$: A profit warning was issued. It is estimated that the core net loss due to shareholders in 2024 is about 1.95 billion to 2.05 billion yuan.
$SHIMAO GROUP (00813.HK)$: Estimated net loss in 2024 is 42.9-43.9 billion yuan. Mainly due to the continued downturn in the real estate industry, gross margins are low and provisions for impairment losses on property projects have increased.
2) Company news
$CHINA WATER (00855.HK)$ : Taikang Asset plans to invest 1.5 billion yuan in the subsidiary Yinlong Water Investment Co., Ltd.
$ZHAOJIN MINING (01818.HK)$: Signed a capital increase agreement with Zijin Investment and Shandong UBS. A total of approximately RMB 0.689 billion will be invested in Shandong UBS according to their respective current shareholding percentages in Shandong UBS, of which the company will invest approximately RMB 0.482 billion.
$CSPC PHARMA (01093.HK)$: The developed SYS 6040 (antibody-conjugated drug) has been approved by the China National Drug Administration and can conduct clinical trials in China. Preclinical studies have shown that this product has good anti-tumor effects on various types of cancer and has high clinical development value.
$HUTCHMED (00013.HK)$: Daveike (tazepastat) has been conditionally approved by the China National Drug Administration for the treatment of recurrent or refractory follicular lymphoma.
3) Repurchase dynamics
$HSBC HOLDINGS (00005.HK)$: Spend HK$0.221 billion to repurchase 2.452 million shares at a repurchase price of HK$89.85 to HK$90.40.
$SWIRE PACIFIC A (00019.HK)$: Approximately HK$37.3586 million was spent to repurchase 0.54 million shares at a repurchase price of HK$10.68-10.86.
